CALC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CalciMedica Inc (CALC) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock lacks positive catalysts, has weak financial performance, and no significant trading signals or recent news to support a bullish case. Given the investor's profile and the current market conditions, holding off on investing in this stock is advisable.
The MACD histogram is positive but contracting, indicating weakening momentum. RSI is neutral at 44.973, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in price direction. The stock is trading below the pivot point of 0.644, with key support at 0.564 and resistance at 0.725.
Oppenheimer maintains an Outperform rating and highlights a $200M opportunity in acute pancreatitis (AP) despite the discontinuation of the Phase 2 KOURAGE trial.
The discontinuation of the Phase 2 KOURAGE trial in acute kidney injury (AKI) removes a major catalyst for the stock. Financials show no revenue growth, and net income remains deeply negative. Analysts have lowered price targets, and there is no recent news or significant trading activity to support upward momentum.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net income of -$10.76M, which improved by 152.70% YoY but remains negative. EPS improved to -0.68, up 106.06% YoY, but still reflects losses. Gross margin remains at 0%.
Mixed analyst sentiment. Oppenheimer lowered the price target from $20 to $10 but maintains an Outperform rating, citing potential in AP. H.C. Wainwright downgraded the stock to Neutral, citing the loss of a major catalyst with the KOURAGE trial discontinuation.
